BofA downgraded Turnstone Biologics to Neutral from Buy with a price target of 50c, down from $10.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSBX:
- Turnstone Biologics Streamlines Operations and Leadership
- Turnstone Biologics announces 60% workforce reduction
- Turnstone Biologics announces leadership transitions
- Turnstone Biologics announces strategic prioritization of its pipeline
- Turnstone Biologics price target lowered to $10 from $12 at BofA